Servier completes the acquisition of Day One Biopharmaceuticals
Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S . in pediatric low-grade glioma. Transaction also includes a strong oncology pipeline of clinical stage assets in rare cancers with high unmet needs....
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio
Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion....